StockUS listing USFATENASDAQHealthcareCapital Destroyer

Fate Therapeutics Inc(FATE) Stock Analysis | Healthcare

USD --+0.00%
Reward30Low
Risk72High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 111.82M
Reward Ratingⓘ30 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on FATE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Fate Therapeutics Inc?

, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.

AI Brief Pro

The brief on Fate Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Fate Therapeutics Inc?

, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 111.82M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (30)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap111.82M
Beta2.666
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
16,582 shares
$14k
0
3-6months
282,747 shares
$204k
0
6-9months
254,536 shares
$103k
0
9-12months
215,779 shares
$17k
0